Introduction {#Sec1}
============

Griffithsin, a high-mannose-specific lectin from *Griffithsia* spp. marine red algae \[[@CR1]\], has broad-spectrum antiviral activity \[[@CR2]\]. Griffithsin is the most potent anti-human immunodeficiency virus (HIV) agent described to date, with a 50% effective concentration (EC~50~) in the low picomolar range \[[@CR3]\]. Moreover, Griffithsin exerts antiviral activity against multiple enveloped viruses including severe acute respiratory syndrome corona virus (SARS-CoV) \[[@CR4]\], Middle East respiratory syndrome coronavirus (MERS-CoV) \[[@CR5]\], hepatitis C virus (HCV) \[[@CR6]\], herpes simplex virus type 2 (HSV-2) \[[@CR7]\] and Japanese encephalitis virus (JEV) \[[@CR8], [@CR9]\], and at least one non-enveloped virus (human papilloma virus) \[[@CR10]\]. Griffithsin showed a favorable safety profile, with no T-cell activating activity and little impact on cytokine and chemokine release by immune cells \[[@CR11]\], as well as an excellent stability over a broad range of pHs, temperatures and protease exposures \[[@CR12], [@CR13]\]. All of these characteristics make Griffithsin an attractive candidate for development as an antiviral therapeutic, but its activity against porcine epidemic diarrhea virus (PEDV) remains unexplored.

PEDV infects pig populations in Asia, Europe and North America, causing huge economic losses \[[@CR14]\]. PEDV is a highly contagious enteric infection characterized by acute watery diarrhea, vomiting and dehydration \[[@CR15]\]. Pigs of all ages can be infected by PEDV, but the infection is especially serious in suckling piglets with morbidity and mortality often reaching 100%.

As an enteropathogenic coronavirus, PEDV has a single-stranded, positive-sense RNA genome approximately 28 kb in size and encoding four structural proteins: the spike (S), envelope (E), membrane (M) and nucleocapsid (N) protein \[[@CR16]\]. The PEDV S protein is a major type I glycoprotein located on the viral surface \[[@CR17]\] containing 27--29 putative *N*-glycosylation sites and plays an important role in viral entry, making it an attractive target for chemotherapeutic interventions.

In this study, we showed that Griffithsin inhibited PEDV infection of Vero cells. We also elucidated the detailed mechanism of Griffithsin's inhibitory action on PEDV infection.

Materials and methods {#Sec2}
=====================

Cells and viruses {#Sec3}
-----------------

Vero cells (an African green monkey-derived kidney cell line) were maintained in Dulbecco's modified Eagle's medium (DMEM) (Gibco, USA) supplemented with 10% (v/v) fetal bovine serum at 37 °C under an atmosphere of 5% CO~2~.

The Chinese PEDV isolate NJ-PEDV was isolated, identified and stored in our laboratory at the National Research Center of Engineering and Technology for Veterinary Biologicals, Jiangsu Academy of Agricultural Science. The NJ-PEDV strain was propagated in Vero cells, and viral stock was titered to determine its TCID~50~.

Protein production {#Sec4}
------------------

Protein production was performed as described in the pET system manual (Novagen, USA) in *E. coli* BL21 (DE3) cells. The Griffithsin gene (GenBank: FJ594069) was codon-optimized for *E. coli* expression, synthesized and cloned into the pUC57 vector by GenScript (Nanjing, China). Then recombinant Griffithsin gene was introduced into pET32a vector to obtain the recombinant expression plasmid pET32a-Griffithsin. Then the plasmid was transformed into competent *E. coli* BL21 (DE3) cells to obtain the recombinant *E. coli* BL21 pET32a-Griffithsin strain which was selected by ampicillin and chloramphenicol, meanwhile pET32a was as a negative control. The recombinant *E. coli* strains were grown overnight at 37 °C in LB broth. Then the overnight cultures were 100-fold diluted in 400 mL of fresh LB broth at 37 °C and induced with 1 mM isopropyl-beta-[d]{.smallcaps}-thiogalactopyranoside (IPTG). After further incubation for 24 h at 15 °C, the protein Griffithsin was extracted and purified using a 5 mL Ni^2+^-Sepharose HisTrap HP™ affinity column (GE Healthcare, Sweden) elution with 300 mM imidazole in PBS. The protein was dialyzed to remove imidazole, following by endotoxin removal using ToxinEraser™ Endotoxin Removal Kit (GenScript, China) and filter sterilization, then quantified using a BCA Protein Assay Reagent Kit (Pierce, USA). Finally, SDS-PAGE and western blotting were used to analyze protein production.

Binding of Griffithsin to PEDV virions by enzyme-linked immunosorbent assay (ELISA) {#Sec5}
-----------------------------------------------------------------------------------

Flat-bottom 96-well microtiter plates (Nunc, Maxiscorp, MD, USA) were coated with either 100 µL of PEDV (1 µg/mL; purified by ultracentrifugation) or 5% (w/v) bovine serum albumin (BSA) in 50 mM carbonate buffer, pH 9.6. After overnight incubation at 4 °C, the wells were blocked with phosphate-buffered saline (PBS) containing 0.05% (v/v) Tween-20 (PBST) and 5% BSA for 2 h at 37 °C. Titrated concentrations of Griffithsin in a volume of 100 µL were added to the wells. For competition ELISA, various dilutions of Griffithsin were pre-incubated with [d]{.smallcaps}-(+)-mannose or [d]{.smallcaps}-(+)-glucose. An anti-His tag antibody (Boster, Wuhan, China) and horseradish peroxidase-conjugated (HRP) secondary antibody (Boster, Wuhan, China) were used to detect Griffithsin binding. For HRP detection, 3,3′,5,5′-tetramethylbenzidine (TMB) substrate was added and the reaction was stopped with 2 M H~2~SO~4~. The absorbance was measured using a microplate spectrophotometer (BioTec) at a wavelength of 450 nm.

Cytotoxicity assay {#Sec6}
------------------

Cytotoxicity was evaluated using a MTT assay. Vero cells were seeded in wells of a 96-well plate at a density of 2 × 10^4^ cells per well. The next day, various concentrations of Griffithsin were added to cells. After incubating for 48 h, MTT was added to each well and incubated for an additional 4 h. The supernatant was removed, dimethyl sulfoxide was added to dissolve the colored formazan crystal and the absorbance was measured at a wavelength of 490 nm.

Antiviral activity of Griffithsin {#Sec7}
---------------------------------

Vero cells were seeded in wells of 96-well plates and cultured overnight at 37 °C under an atmosphere of 5% CO~2~. Various concentrations of Griffithsin (0--8 µg/mL) were incubated with PEDV for 30 min at room temperature and subsequently used to infect cells at a multiplicity of infection (MOI) of 3 and 5 for 1 h at 37 °C. The cells were washed with PBS, and fresh medium containing 2% fetal bovine serum was added. In a control group, Griffithsin was pre-incubated with 100 mM [d]{.smallcaps}-(+)-mannose before incubation with PEDV. After 24 h, the cells were fixed with pre-cooled methanol for 10 min, air-dried, and blocked with PBS containing 3% BSA for 1 h. Then, cells were then incubated with mouse anti-PEDV monoclonal antibody (diluted 1:200; a generous gift from Haoming Zhang) and FITC-conjugated goat anti-mouse IgG (diluted 1:50; Boster, Wuhan, China) for 1 h each at 37 °C. After washing, the cells were stained with DAPI for 10 min at room temperature, washed again and observed using a Cytation™ five Cell Imaging Multi-Mode Reader (BioTek).

Time-of-addition assay {#Sec8}
----------------------

The time-of-addition assay for Griffithsin was conducted as previously described with some modifications \[[@CR18]\]. Subconfluent Vero cell monolayers were infected with PEDV at a MOI of 3 for 1 h at 37 °C. After washing with PBS, 8 µg/mL Griffithsin was added to the cells either before (− 1 h), during (0 h) or after (1, 2, 4, 6, 8, 12, or 24 h) PEDV infection. Infected cells not treated with Griffithsin were used as a control. After 24 h, cells were collected and subjected to RT-qPCR.

Total RNA was extracted using a MiniBEST Universal RNA Extraction Kit (TaKaRa, Osaka, Japan). RNA was reverse transcribed into first-strand cDNA using PrimeScript™ Reverse Transcriptase (TaKaRa). RT-qPCR was performed with a LightCycler 480 II System (Roche, Basel, Switzerland) using the EvaGreen 2 × qPCR MasterMix-No Dye kit (abm, Canada) according to the manufacturer's recommendations. The forward primer (FP) and reverse primer (RP) for the PEDV M gene and the GAPDH gene were as follows: PEDV-FP:5′-ACTCTGCGTTCTTGTATG-3′, PEDV-RP:5′-CAACCGAATGCTATTGAC-3′, GAPDH-FP: 5′-CCTTCCGTGTCCCTACTGCCAAC-3′, GAPDH-RP: 5′-GACGCCTGCTTCACCACCTTCT-3′. Data were analyzed using the 2^−ΔΔCt^ method. The mean RNA level of control cells not treated with Griffithsin was assigned a value of 1. Each assay was performed in triplicate.

Effect of Griffithsin on viral entry stages {#Sec9}
-------------------------------------------

For the attachment assay, Vero cells in wells of 96-well plates were pre-cooled at 4 °C for 30 min and simultaneously infected with PEDV (MOI = 3) and treated with Griffithsin for 1 h at 4 °C. For the penetration assay, PEDV virions were allowed to attach to cells at 4 °C for 1 h. After washing with PBS, the cells were simultaneously warmed to 37 °C and treated with Griffithsin for an additional 1 h. Finally, the cells were washed with PBS and collected for RT-qPCR analysis as described above. Cells not treated with Griffithsin were used as a control.

Cell-to-cell spread assay {#Sec10}
-------------------------

Cell-to-cell spread was assessed as previously described \[[@CR7], [@CR19]\] with some modifications. Vero cells were incubated with PEDV (MOI = 3) at 37 °C for 3 h and washed with PBS to remove unbound virions. Then cells were cultured in fresh medium containing Griffithsin and monoclonal neutralizing antibody (nAb) (a generous gift from Haoming Zhang). Cells cultured in medium containing nAb but no Griffithsin served as a control. After 48 h incubation, the cells were fixed with pre-cooled methanol for indirect immunofluorescence assays.

Data analysis {#Sec11}
-------------

Data were presented as the means ± standard deviations of three independent experiments. Differences between group means were analyzed using the Student's *t* test with GraphPad Prism 6 software. Statistical significance was assumed for *P* \< 0.05.

Results {#Sec12}
=======

Expression of recombinant Griffithsin {#Sec13}
-------------------------------------

We designed a recombinant gene encoding Griffithsin with a His6 tag at it C-terminus. Recombinant Griffithsin was analyzed by SDS-PAGE and western blotting using anti-His monoclonal antibody as shown in Fig. [1](#Fig1){ref-type="fig"}. We observed a band of the expected molecular weight (12.7 kDa). The majority of the recombinant Griffithsin protein was present in the *E. coli* cytoplasm in soluble form. The purified protein was dialyzed, following by endotoxin removal and filter sterilization prior to use.

Fig. 1Characterization of recombinant Griffithsin. **a** Using SDS-PAGE. Lane M protein size markers, Lane 1 supernatant of *E. coli* bearing recombinant expression vector after induction with IPTG and high-pressure homogenization, Lane 2 pellet of *E. coli* bearing recombinant expression vector after induction with IPTG and high-pressure homogenization, Lane 3 total cell extract of *E. coli* bearing recombinant expression vector without induction by IPTG, Lane 4 Griffithsin purified by nickel affinity chromatography. **b** Western blotting analysis using an anti-His tag antibody. Lane 1 Griffithsin purified by nickel affinity chromatography

Binding of Griffithsin to PEDV {#Sec14}
------------------------------

To investigate whether Griffithsin could bind to PEDV, we performed ELISA against immobilized PEDV virions as previously described \[[@CR20]\]. The ELISA experiment demonstrated that Griffithsin could bind to PEDV in a dose-dependent manner as shown in Fig. [2](#Fig2){ref-type="fig"}. Moreover, Griffithsin binding to PEDV was efficiently inhibited when it was pre-incubated with mannose or glucose (Fig. [2](#Fig2){ref-type="fig"}), indicating that PEDV glycans may be involved in the binding of Griffithsin to PEDV. These data implied potential antiviral activity of Griffithsin against PEDV.

Fig. 2ELISA binding of Griffithsin (circles), Griffithsin pre-incubated with mannose (squares) or Griffithsin pre-incubated with glucose (triangles) to PEDV virions

Griffithsin inhibits PEDV infection of Vero cells {#Sec15}
-------------------------------------------------

Antiviral assays were performed to determine whether binding of Griffithsin to PEDV affected its infectivity. The effects of Griffithsin at concentrations of 1, 2, 4, 8 µg/mL on PEDV infection of Vero cells are shown in Fig. [3](#Fig3){ref-type="fig"}. Pre-incubation of PEDV with Griffithsin resulted in a significant reduction in infection compared with untreated PEDV virions. After infection of Vero cells with PEDV at a MOI of 5, the infection rate decreased from 92.5% (in the absence of Griffithsin treatment) to 60% and 14.43% in the presence of 1 µg/mL and 8 µg/mL Griffithsin, respectively. Griffithsin exhibited a much stronger inhibitory effect when Vero cells were infected at a MOI of 3: the infection rate decreased from 89.1% (in the absence of Griffithsin treatment) to 47.5% and 6.3% in the presence of 1 µg/mL and 8 µg/mL Griffithsin, respectively. As shown in Fig. [3](#Fig3){ref-type="fig"}, Griffithsin inhibited PEDV infection in a dose-dependent manner, and its inhibitory effect was lost when Griffithsin was pre-incubated with mannose.

Fig. 3Anti-PEDV activity of Griffithsin detected by immunofluorescence microscopy. **a** Indirect immunofluorescence assay of PEDV-infected Vero cells was performed to detect the antiviral activity of increasing concentrations of Griffithsin. N.I.: non-infected control. **b** Quantitation of PEDV-infected cells after treatment of Griffithsin. The results are expressed as percent-infected cells calculated from the number of infected cells (FITC stain)/total number of cells (DAPI nuclei stain) × 100%. Each value represents the mean of three independent experiments and its standard deviation. \**P* \< 0.05, \*\**P* \< 0.01 and \*\*\**P* \< 0.001 compared with the 0 µg/mL control group. In both **a** and **b**, 8 + M: Griffithsin at concentration of 8 µg/mL was pre-incubated with mannose

The cytotoxicity of Griffithsin against Vero cells was studied, and the results showed that the proliferative activity of Vero cells was unaffected by Griffithsin at concentrations ranging from 1 to 10 µg/mL. These results suggested that Griffithsin possessed antiviral activity against PEDV but no cytotoxic activity against mammalian cells.

Time course of Griffithsin addition {#Sec16}
-----------------------------------

A time-of-addition assay was conducted to evaluate whether Griffithsin's inhibitory efficacy varied during different periods of PEDV infection (before, during and after). Viral RNA levels in Vero cells were quantitated 24 h after the last Griffithsin addition. Surprisingly, as shown in Fig. [4](#Fig4){ref-type="fig"}, addition of Griffithsin resulted in a significant reduction of viral RNA levels at all time points compared with the virus alone control (*P* \< 0.001). Moreover, we found that delayed addition of Griffithsin resulted in a weaker inhibitory effect on PEDV. Griffithsin completely suppressed PEDV infection when added before or during virus inoculation (0 h); however, viral RNA loads exhibited similar reductions when Griffithsin was added after virus inoculation (1, 2, 4, 6, 8, 12 h). By contrast, Griffithsin showed only a modest inhibitory effect when added 24 h post-virus inoculation, with viral RNA loads 135-fold higher compared with addition 12 h post-inoculation. These data indicated that Griffithsin had a stronger inhibitory effect during the initial stages of PEDV infection.

Fig. 4Effect of Griffithsin on PEDV entry stages. In the control group, cells were infected with PEDV without Griffithsin treatment at any stage. Data are presented as means ± standard deviations of three independent experiments. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001 compared with the control group

Effect of Griffithsin on PEDV entry stages {#Sec17}
------------------------------------------

To further understand the antiviral mechanisms of Griffithsin against PEDV, its effect on viral attachment and penetration was evaluated. The results clearly showed that Griffithsin could block viral attachment and had only modest effects on viral penetration (Fig. [5](#Fig5){ref-type="fig"}). The attachment assay showed that viral RNA loads were reduced approximately tenfold compared with control cells (*P* \< 0.001). However, Griffithsin had little effect on infection when added during viral penetration (*P* \> 0.05). Viral RNA loads were unaffected by Griffithsin addition compared with the control group when it was pre-incubated with mannose.

Fig. 5Time-of-addition effect of Griffithsin on PEDV infection on Vero cells. Viral loads were quantitated using RT-qPCR. 8 + M: Griffithsin at concentration of 8 µg/mL was pre-incubated with mannose. Data are presented as means ± standard deviations of three independent experiments. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001 compared with the control group

Griffithsin inhibits cell-to-cell spread of PEDV {#Sec18}
------------------------------------------------

Although it was uncertain whether PEDV can spread by direct cell-to-cell contact without passing through a cell-free stage, cell-to-cell spread has been observed in studies of many enveloped viruses. Thus, we speculated that cell-to-cell spread of PEDV could be inhibited by Griffithsin. A monoclonal nAb was added to completely neutralize any released virions. PEDV cell-to-cell transmission was clearly efficiently suppressed by Griffithsin, as shown in Fig. [6](#Fig6){ref-type="fig"}a, b, which caused a significant reduction in the number of PEDV-infected cells in a dose-dependent manner. The infection rate was reduced from 65.3% in cells treated with nAb alone to 27.3% and 12% in cells treated with 4 µg/mL and 8 µg/mL Griffithsin, respectively. Interestingly, the infection rate was reduced to 36.3% which showed stronger antiviral activity compared with the group treated with nAb alone. Importantly, Griffithsin also promoted the formation of discrete foci of infection.

Fig. 6Effect of Griffithsin treatment on PEDV cell-to-cell spread using immunofluorescence microscopy. **a** An indirect immunofluorescence assay was performed to assess the effect of Griffithsin on cell-to-cell spread of PEDV. **b** Quantitation of PEDV-infected cells after treatment with Griffithsin. Each value represents the mean of three independent experiments and its standard deviation. "−": no nAb was added, "+": nAb was added, Arabic numerals 0, 4, 8: the concentration of Griffithsin

Discussion {#Sec19}
==========

In this study, we provided initial evidence that Griffithsin has antiviral activity against PEDV. Moreover, its antiviral mechanism of action means that Griffithsin may represent an attractive drug for chemotherapeutic intervention. Griffithsin was not only able to prevent infection by cell-free virus, but was also able to prevent viral spread between infected and uninfected cells. This property may make Griffithsin superior to other antiviral drugs. Thus, Griffithsin may be a promising tool in combating PEDV.

Griffithsin bound PEDV in a glycan-dependent manner indicating that Griffithsin's antiviral activity may depend on interactions with viral glycans. We demonstrated that 8 µg/mL Griffithsin reduced infection by 82.8% when Vero cells were infected with PEDV at a MOI of 3. Furthermore, 4 µg/mL Griffithsin reduced PEDV infection of Vero cells by 69.2%; by contrast, the same concentration reduced infection by 76.9% when Marc-145 cells were infected with PRRSV at a MOI of five in our previous study. Griffithsin also displayed antiviral activity against other enveloped viruses to various degrees and had much more potent activity against HIV compared with the results shown here for PEDV \[[@CR2]\]. The reasons underlying this difference are not completely understood, but the following potential causes may provide part of the explanation. Firstly, the structure and composition of glycans, as well as the glycosylation level of envelope glycoproteins, may affect the binding affinity of Griffithsin which is a major determinant of its antiviral activity. Secondly, the density of envelope spikes may be an important factor in determining Griffithsin activity. HIV-1 virions have an average of 14 spikes per virion particle \[[@CR21]\] (compared with 450 for influenza type A virus \[[@CR22]\]) and as few as four spikes are sufficient for HIV infection \[[@CR23]\]; thus, to block infection by one HIV virion, Griffithsin must neutralize only four spikes. This probably explains why Griffithsin displayed a stronger inhibitory effect on HIV infection compared with other enveloped viruses.

Our data clearly showed that Griffithsin could block viral adsorption and had only modest effects on viral penetration. Most interestingly, we found that Griffithsin could inhibit PEDV infection by blocking cell-to-cell transmission. Our previous study showed that Griffithsin displayed antiviral activity against PRRSV by blocking virion attachment but not viral penetration. Moreover, studies have shown that the inhibition of MERS-CoV by Griffithsin might result from a failure of the virus to attach to target cells \[[@CR5]\]. By contrast, Nixon reported that Griffithsin inhibited HSV-2 infection by disrupting cell-to-cell spread, not by acting on the entry stage \[[@CR7]\]. The reason for this difference in mechanism of action may be related to the virus itself and its receptors. The detailed mechanisms remain to be explored in the future studies.

To understand the mechanism of action of Griffithsin on PEDV in more detail, we assessed Griffithsin's inhibitory efficacy when it was added at different stages of PEDV infection. Griffithsin treatment caused a significant reduction of viral RNA loads at all times of addition. Addition of Griffithsin before and during viral inoculation (0 h) caused a 10^5^-fold reduction in viral loads compared with uninfected cells; by contrast, addition of Griffithsin 1--2, 4--12 and 24 h post-inoculation caused 10^4^-, 10^3^- and eightfold reductions in viral loads, respectively. This finding indicated that earlier treatment with Griffithsin resulted in stronger inhibitory effects against PEDV infection.

The antiviral activity of Griffithsin in vivo has been widely studied. The in vivo efficacy of Griffithsin against SARS-CoV \[[@CR24]\], HSV-2 \[[@CR7]\], JEV \[[@CR9]\] and HCV \[[@CR6], [@CR25]\] was evaluated in murine models, and the results showed that Griffithsin treatment had a protective effect as shown by animal weight, morbidity, mortality and target tissue viral titer. Interestingly, Barry and his colleagues \[[@CR24]\] indicated that SARS-CoV-infected mice treated with Griffithsin did not lose weight and had 100% survival; however, mice not treated with Griffithsin experienced a 25% decrease in weight and had just a 30% survival rate. Moreover, bioavailability studies \[[@CR26], [@CR27]\] in animals demonstrated that Griffithsin could accumulate to high levels in serum after subcutaneous delivery and that serum from Griffithsin-treated animals retained antiviral activity; these findings suggested that Griffithsin may be a promising candidate as a systemic antiviral therapeutic. Further studies in live animals will be necessary to confirm the value of inhibiting PEDV infection in vivo, potentially leading to a new antiviral intervention.

In conclusion, we found that Griffithsin had potent anti-PEDV activity via prevention of viral attachment and cell-to-cell spread. Moreover, our study revealed that Griffithsin exhibited a stronger effect on PEDV infection when it was added during early stages of infection. Further studies in live animals will be necessary to develop a novel antiviral strategy for PEDV therapy.
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